The ACIP recommends PCV20 or PCV21 over 23-valent pneumococcal polysaccharide vaccine (PPSV23) as an option to complete a vaccine series in adults aged 19 years and older who have started their ...

Overall, AstraZeneca’s data will illuminate its commitment to reducing the global burden of infectious diseases through innovative vaccine and antibody therapies. (PRESS RELEASE) CAMBRIDGE, 8-Apr-2025 ...

Doncaster and Bassetlaw Teaching Hospitals (DBTH) is encouraging those aged 65 and over to get their shingles and pneumococcal vaccines when offered, echoing the ongoing campaign by the NHS and ...

Doncaster and Bassetlaw Teaching Hospitals (DBTH) is encouraging those aged 65 and over to get their shingles and pneumococcal vaccines when offered, echoing the ongoing campaign by the NHS and ...

In addition to helping guide future vaccine designs, the hu1B7 and hu11E6 antibodies themselves hold promise as therapeutic medicines for infected and high-risk infants. Previous work by Maynard ...

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

Main outcome measures Having received the first dose of a vaccine against COVID-19 by 15 March 2021. We calculated vaccination rates and estimated unadjusted and adjusted ORs using logistic regression ...

The PCV13 vaccine makes it easier for the immune system to attack S. pneumoniae and produce antibodies by linking the polysaccharide capsule layer to proteins. Exposure to neonatal antibiotics reduces ...

No serious adverse events were considered to be related to the study vaccines. Post-dose 3, the VAX-24 Mid dose met target precedent Phase 2 non-inferiority (NI) criteria on relative ...

Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine ...

"IgG4 is primarily involved in regulatory functions, and is associated with immune tolerance and chronic antigen exposure," while IgG2 targets "polysaccharide ... the antibody class switch, which was ...

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has completed the on-site work for Phase III clinical trials and plans to submit a pre-application for market registration to the National ...